PT  - JOURNAL ARTICLE
AU  - IKKO TOMISAKI
AU  - MIRII HARADA
AU  - KEI TOKUTSU
AU  - AKINORI MINATO
AU  - YUJIRO NAGATA
AU  - RIEKO KIMURO
AU  - MASAHIRO MATSUMOTO
AU  - NAOHIRO FUJIMOTO
TI  - Impact of C-reactive Protein Flare Response in Patients With Advanced Urothelial Carcinoma Who Received Pembrolizumab
AID  - 10.21873/invivo.12659
DP  - 2021 Nov 01
TA  - In Vivo
PG  - 3563--3568
VI  - 35
IP  - 6
4099  - http://iv.iiarjournals.org/content/35/6/3563.short
4100  - http://iv.iiarjournals.org/content/35/6/3563.full
SO  - In Vivo2021 Nov 01; 35
AB  - Background/Aim: To clarify the clinical significance of the temporary elevated C-reactive protein (CRP) levels followed by a decrease below baseline (CRP flare response) after administration of pembrolizumab to patients with advanced urothelial carcinoma (UC). Patients and Methods: We retrospectively reviewed 31 patients with advanced UC who received pembrolizumab. Patients were categorized into 3 groups (flare-responder, responder, non-responder) according to early CRP kinetics. Intergroup tumor response and survivals were compared. Results: Objective response rates of flare-responder, responder, and non-responder groups were 75%, 80%, and 26%, respectively. Median overall survival was not reached in flare-responder and responder groups, and was 10.2 months in the non-responder group (p=0.03). Furthermore, the flare-responder group did not reach median progression-free survival, and for the responder and non-responder groups it was 15.2 and 2.8 months, respectively (p=0.03). Conclusion: CRP flare response might be a promising biomarker in patients with advanced UC who received pembrolizumab.